Scholarlink

Background <p>Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a&#xa0;suitable treatment option for many patients and is increasingly establishing itself as a&#xa0;key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC).</p> Objective <p>This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.</p> Methods <p>Presentation of key study results, current approval labels and ongoing clinical trials.</p> Results <p>Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Radionuklidtherapie 2025: Optionen der Nuklearmedizin in der Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms

  • 期刊论文

  • 发表日期：

    2025年2月21日

查看全文
  • Luisa Willner,
  • Robert Tauber,
  • Matthias Eiber

摘要

Background

Radionuclide therapy continues to gain in importance thanks to promising clinical results. It is a suitable treatment option for many patients and is increasingly establishing itself as a key pillar in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Objective

This article summarizes the current role of radionuclide therapies in the treatment of mCRPC and provides insights into recent developments.

Methods

Presentation of key study results, current approval labels and ongoing clinical trials.

Results

Significant prolongation of survival through treatment with lutetium-177-PSMA-617 and radium-223-dichloride has led to approval of both substances in late-stage mCRPC. Further study results on the effectiveness of lutetium-PSMA in earlier stages and on the use of the alpha emitter actinium-225 are expected.